agilon health stock: Q3 profit returns as outlook rises

agilon health reported a return to third-quarter profit on November 4, 2026, and raised its full-year outlook. The release, published by StockTitan, showed stronger revenue and lower medical services costs despite fewer members on the platform.

Quarterly profit changes the picture

Revenue for the quarter ended September 30, 2026, rose 6 percent to 1.519 billion US dollars from 1.435 billion US dollars a year earlier. Net income was 34.9 million US dollars, compared with a loss of 110.2 million US dollars in the prior-year quarter. Diluted earnings per share were 1.97 US dollars, versus a loss of 6.65 US dollars.

Adjusted EBITDA reached 63.7 million US dollars after a loss of 91.5 million US dollars in the year-earlier period. The medical services expense ratio fell to 88.5 percent from 104.0 percent, although the company said favorable claims development from the first half of 2026 contributed to the improvement.

Higher guidance, smaller platform

Agilon raised its 2026 revenue guidance to a range of 5.870 billion to 5.890 billion US dollars from 5.775 billion to 5.860 billion US dollars previously. The new Adjusted EBITDA range is 145 million to 155 million US dollars, up from 75 million to 95 million US dollars.

Total platform membership fell 8 percent year over year to 566,000 at the end of September. Medicare Advantage members declined 10 percent to 454,000, while ACO model beneficiaries fell 3 percent to 112,000. The company attributed the membership changes primarily to a focus on profitable contracting, previously disclosed market exits and measured growth.

Business model and market position

agilon health partners with physician groups and health systems to help them move senior patients into a value-based Total Care Model. Its platform combines technology, people, capital, operating processes and a peer network for primary care physicians, with operations in approximately 30 communities in the United States. The model targets care coordination, clinical outcomes and medical-cost management rather than fee-for-service volume.